Table 2.
Toxicity | Incidence (incidence in studies directly reporting only) |
---|---|
Alopecia | “Most”a |
Erythema | 8.2% (37.6%) |
Nausea/vomiting | 1.3% (11.3%) |
Headache/orbital pain | 6.2% (11.8%) |
Anterior inflammation (blepharitis/conjunctivitis/keratitis/iritis) | 2.8% (9.7%) |
Lacrimal dysfunction | 5.6% (14.0%) |
Cataract | 2.8% (21.3%) |
Retinopathy | 3.9% (10.4%) |
Optic neuropathy | 0.6% (5.8%) |
Pituitary dysfunction | 2.1% (10.5%) |
Notes: Total incidence of reported side effects based on all available studies and patients (n=466). It should be noted that these results are subjected to significant reporting bias, as where studies have not reported a specific side effect, it is unclear whether this side effect was absent or merely not commented upon (particularly for common or minor toxicity). The (X%) results indicate incidence only in those studies where the side effect was specifically commented upon. It is likely that the true incidence lies between these two values.
Several larger studies reported alopecia in most or all patients, without giving a numerical value.